<DOC>
	<DOCNO>NCT00944684</DOCNO>
	<brief_summary>Treatment patient chronic hepatitis C infect genotype 1 hepatitis C virus ( HCV ) consist combine peginterferon/ribavirin 48 week . Approximately 50 % patient experience sustain virological response equal cure . All patient either respond experience recurrence HCV virus chronic hepatitis . Important predictor successful treatment sustain dose peginterferon ribavirin . With regard latter , clinical evidence indicate high ribavirin dos may fact even improve treatment outcome . However , high ribavirin dos cause hemolytic anemia require dose reduction . Recent clinical experience show erythropoetic growth factor , include erythropoetin , counteract hemolytic anemia cause antiviral treatment chronic hepatitis C patient . Therefore , current trial aim test whether high ribavirin dos adapt target plasma concentration instead weight-based dose result well healing rate , whether ribavirin-associated hemolytic anemia compensate concommitant erythropoetin treatment . Using randomize , control , open-label design , investigator hypothesize patient high ribavirin dos adapt plasma level experience well viral clearance patient treated standard weight-based ribavirin dos . In addition , investigator hypothesize erythropoetin treatment counteract hemolytic anemia induce ribavirin thereby allow maintenance target plasma concentration without ribavirin dose reduction .</brief_summary>
	<brief_title>High Dose Ribavirin Treatment Chronic Hepatitis C</brief_title>
	<detailed_description>Background Prevalence incidence chronic hepatitis C ( CHC ) rise worldwide . Complications include chronic liver failure hepatocellular carcinoma , chronic hepatitis C major indication liver transplantation . Effective treatment require prevent outcomes . Current treatment consist combination peginterferon ( PegIFN ) ribavirin ( RBV ) give 24 48 week depend viral genotype . While genotype 2 3 respond well 24 week PegIFN/RBV approximately 80 % viral clearance , genotype 1 infected patient achieve 40-50 % sustained viral response ( SVR ) 48 week combination therapy . RBV nucleoside analog structural similarity guanosine , modulate RNA DNA synthesis . RBV reveal antiviral activity respiratory syncytial ( RS ) -virus , influenza virus , Lassa virus uand others . The exact mode antiviral activity yet unknown believe relate reduce survival HCV-infected hepatocytes thereby allow elimination infect cell interferon-stimulated immune mechanism . Generally , RBV well tolerate . With standard daily dose 1.000 1.200mg , irritability , sleep abnormality , cough pruritus . The prevalent typical side effect RBV dose-dependent hemolytical anemia respond well dose reduction interruption RBV therapy . RBV-associated anemia impairs quality life , overall , 25-36 % patient require dose reduction and/or RBV cessation . However , reduction/cessation RBV associate significant drop SVR measure maintain RBV dose clearly warrant . Several recent study show erythropoetin counteract RBV-induced hemolytic anemia , improve quality life . The relevance RBV dose regard therapeutic response combination therapy well-established currently , RBV dose accord weight : patient CHC genotype 1 treat 1.000mg body weight &lt; 65kg , receive 1.200mg &gt; 65kg . Retrospective study show relapsers non-responders antiviral treatment RBV low RBV level SVR . In retrospective analysis 4 study investigate total 1105 patient treat RBV , RBV plasma concentration measure 4 week treatment correlate viral clearance : SVR 31.8 % RBV level &lt; 1,000ng/ml , increase 62.5 % RBV concentration &gt; 4,000ng/ml . A pilot trial Sweden investigate whether dose RBV accord plasma level 15mcmol/l ( 3.7mcg/ml ) 10 patient . Median RBV dose 2.540mg/day patient receive erythropoetin.SVR achieve 9 10 patient . So far , randomize , control trial compare weight-based RBV ( standard ) vs. RBV dose accord kidney function plasma level . Objective Comparison efficacy tolerability treatment PegIFN-alpha 2a + RBV dose accord plasma concentration vs PegIFN-alpha 2a + weight-based RBV patient chronic hepatitis C genotype 1 Methods Prospective , control , open label randomize human trial</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Male female patient age 1865 year Elevated liver enzymes level Compensated liver disease Available liver histology confirm METAVIR F2 fibrosis Written consent participation Exclusion Criteria Age &lt; 18 , &gt; 65 Prior ribavirin treatment Intolerance towards ribavirin , PegIFN erythropoetin Pregnancy breast feeding Relevant cardiovascular pulmonary disease Kidney insufficiency ( creatinine clearance &lt; 50ml/min ) Coinfection HIV hepatitis B virus Hepatic comorbidities ( hemochromatosis , Wilson 's disease , autoimmune disorder ) Alcohol consumption &gt; 40g/day Psychiatric disorder Malignancy ( except basalioma ) Active consumption illicit drug Participation another trial shorter 3 month prior inclusion Lack consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Chronic hepatitis C</keyword>
	<keyword>Antiviral treatment</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>Sustained virological response</keyword>
	<keyword>Hemolytic anemia</keyword>
	<keyword>Erythropoetin</keyword>
</DOC>